Endonovo Therapeutics, Inc. (ENDV)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Endonovo Therapeutics, Inc. (ENDV) with AI Score 43/100 (Weak). Endonovo Therapeutics, Inc. is a biotechnology company focused on developing and distributing non-invasive Electroceutical medical devices for regenerative medicine. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Endonovo Therapeutics, Inc. (ENDV) Healthcare & Pipeline Overview
Endonovo Therapeutics, Inc., operating in the biotechnology sector, develops and distributes non-invasive Electroceutical medical devices, including SofPulse, for regenerative medicine applications. The company targets palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain, positioning itself within the electroceuticals market.
Investment Thesis
Endonovo Therapeutics operates in the electroceuticals market, a growing segment within regenerative medicine. The company's focus on non-invasive devices offers a potential advantage over traditional treatments. The SofPulse device addresses a significant market for palliative treatment of soft tissue injuries and chronic wounds. However, the company's financial performance, as indicated by a negative P/E ratio of -0.04 and a market cap of $0.00B, raises concerns about its current profitability and valuation. The high beta of -9.79 suggests significant volatility. Future growth depends on successful clinical trials and regulatory approvals for its expanded applications, including cardiovascular and liver diseases. Investors should carefully consider the risks associated with OTC-traded companies and the uncertainty surrounding the company's long-term financial viability.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.00B indicates a micro-cap company with limited resources and higher risk.
- Negative P/E ratio of -0.04 reflects the company's current lack of profitability.
- Beta of -9.79 suggests an inverse correlation with the market, but also indicates high volatility.
- The company's focus on electroceuticals positions it in a growing segment of the regenerative medicine market.
- SofPulse device targets a significant market for palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain.
Competitors & Peers
Strengths
- Proprietary Electroceutical technology
- Non-invasive treatment approach
- Potential for expanded applications
- Focus on regenerative medicine
Weaknesses
- Limited financial resources
- Lack of profitability
- Dependence on regulatory approvals
- OTC market trading
Catalysts
- Upcoming: Clinical trial results for SofPulse in treating chronic wounds.
- Upcoming: Regulatory approvals for expanded applications of Electroceuticals in cardiovascular disease.
- Ongoing: Research and development of new Electroceutical devices for regenerative medicine.
- Ongoing: Partnerships with healthcare providers for product adoption and distribution.
- Ongoing: Expansion into international markets.
Risks
- Potential: Failure to obtain regulatory approvals for new applications.
- Potential: Competition from established pharmaceutical companies and medical device manufacturers.
- Potential: Negative clinical trial results for SofPulse or other Electroceutical devices.
- Ongoing: Limited financial resources and lack of profitability.
- Ongoing: Risks associated with OTC market trading, including low liquidity and potential for price manipulation.
Growth Opportunities
- Expansion of SofPulse Applications: Endonovo Therapeutics has the opportunity to expand the applications of its SofPulse device beyond its current indications. The market for chronic wound care is estimated to reach billions of dollars, and SofPulse could capture a significant share with successful clinical trials and marketing efforts. Timeline: Ongoing clinical trials with potential results within the next 12-24 months.
- Treatment of Cardio Chronic Kidney Disease: The company is exploring the use of its Electroceuticals medical device for the treatment of cardio chronic kidney disease. This represents a significant market opportunity, as chronic kidney disease affects millions of people worldwide. Successful development and commercialization of this application could drive substantial revenue growth. Timeline: Pre-clinical and early clinical trials ongoing, with potential for Phase 2 trials within 2-3 years.
- Treatment of Liver Disease NASH: Endonovo Therapeutics is also targeting liver disease non-alcoholic steatohepatitis (NASH) with its Electroceuticals technology. NASH is a growing health concern with limited treatment options, presenting a substantial market opportunity. Timeline: Pre-clinical studies underway, with potential for clinical trials in 3-5 years.
- Cardiovascular and Peripheral Artery Disease (PAD) Applications: The company is investigating the use of its Electroceuticals device for cardiovascular and peripheral artery disease (PAD). These conditions affect a large segment of the population, and a non-invasive treatment option could be highly valuable. Timeline: Early-stage research and development, with potential for pre-clinical studies in 2-3 years.
- Ischemic Stroke Treatment: Endonovo Therapeutics is exploring the application of its Electroceuticals technology for the treatment of ischemic stroke. Stroke is a leading cause of disability and death, and new treatment options are urgently needed. Timeline: Early-stage research and development, with potential for pre-clinical studies in 3-5 years.
Opportunities
- Expansion into new therapeutic areas
- Partnerships with healthcare providers
- International market expansion
- Growing demand for non-invasive therapies
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Technological advancements by competitors
- Negative clinical trial results
Competitive Advantages
- Proprietary Electroceutical technology
- Patents protecting device designs and applications
- First-mover advantage in specific electroceutical applications
- Potential for strong brand recognition with successful clinical outcomes
About ENDV
Endonovo Therapeutics, Inc., founded in 2008 and headquartered in Woodland Hills, California, is a biotechnology company specializing in the development, manufacture, and distribution of non-invasive Electroceutical medical devices. The company's core focus is regenerative medicine, with a mission to provide innovative solutions for various medical conditions through its proprietary technology. Its flagship product, SofPulse, is a non-invasive Electroceutical therapeutic device designed for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Beyond SofPulse, Endonovo Therapeutics is exploring the application of its Electroceuticals medical device for treating a range of conditions, including cardio chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular, peripheral artery disease (PAD), and ischemic stroke. The company's business model centers on the development, manufacturing, and marketing of these devices to healthcare providers and patients. Endonovo Therapeutics operates primarily in the United States, with potential for future expansion into international markets as regulatory approvals are secured for its various applications.
What They Do
- Develops non-invasive Electroceutical medical devices.
- Manufactures Electroceutical devices for regenerative medicine.
- Distributes Electroceutical devices to healthcare providers and patients.
- Offers SofPulse, a therapeutic device for soft tissue injuries, chronic wounds, and post-operative pain.
- Researches and develops new applications for Electroceutical technology.
- Targets treatment of cardio chronic kidney disease, liver disease NASH, cardiovascular, PAD, and ischemic stroke.
Business Model
- Develops and patents Electroceutical medical device technology.
- Manufactures and distributes SofPulse for palliative treatment.
- Seeks regulatory approvals for expanded applications of Electroceuticals.
- Partners with healthcare providers for product adoption and distribution.
Industry Context
Endonovo Therapeutics operates within the biotechnology industry, specifically focusing on the electroceuticals market. This market is experiencing growth driven by increasing demand for non-invasive therapies and advancements in medical device technology. The competitive landscape includes companies developing similar electroceutical devices and traditional pharmaceutical companies offering alternative treatments. Endonovo's success depends on its ability to differentiate its products, secure regulatory approvals, and establish strong market presence. The biotechnology industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition.
Key Customers
- Hospitals and clinics
- Physicians and medical professionals
- Patients with soft tissue injuries, chronic wounds, and post-operative pain
- Patients with cardio chronic kidney disease, liver disease NASH, cardiovascular, PAD, and ischemic stroke (future)
Financials
Chart & Info
Endonovo Therapeutics, Inc. (ENDV) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
-
Stocks That Hit 52-Week Lows On Friday
· Feb 28, 2020
-
Stocks That Hit 52-Week Lows On Thursday
· Feb 27, 2020
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ENDV.
Price Targets
Wall Street price target analysis for ENDV.
MoonshotScore
What does this score mean?
The MoonshotScore rates ENDV's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
ENDV OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Endonovo Therapeutics may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading in these securities carries a higher degree of risk compared to stocks listed on major exchanges like the NYSE or NASDAQ. This tier often includes companies that are distressed, defunct, or unwilling to provide current information.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure
- Low trading volume and liquidity
- Potential for price manipulation
- Higher risk of fraud or scams
- Lack of regulatory oversight
- Verify the company's registration and legal standing.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Research the management team and their track record.
- Understand the risks associated with OTC trading.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal issues.
- Company has been in operation since 2008.
- Focus on developing medical devices for regenerative medicine.
- SofPulse device targets a specific market for palliative treatment.
- Company has a website and publishes press releases.
Endonovo Therapeutics, Inc. Stock: Key Questions Answered
What does Endonovo Therapeutics, Inc. do?
Endonovo Therapeutics, Inc. is a biotechnology company that develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. Its primary product, SofPulse, is designed for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain. The company is also exploring the use of its Electroceuticals technology for treating cardio chronic kidney disease, liver disease NASH, cardiovascular, PAD, and ischemic stroke. Endonovo's business model centers on developing and commercializing these devices to improve patient outcomes and address unmet medical needs.
What do analysts say about ENDV stock?
AI analysis is currently pending for ENDV. Given the company's OTC listing, limited financial information, and lack of profitability, analysts may express caution regarding its investment potential. Key valuation metrics, such as the negative P/E ratio, reflect the company's current financial challenges. Growth considerations will likely focus on the successful development and commercialization of its Electroceutical devices and the achievement of regulatory approvals for expanded applications. The high beta suggests significant volatility, which could deter risk-averse investors.
What are the main risks for ENDV?
The main risks for Endonovo Therapeutics, Inc. include its limited financial resources, lack of profitability, and dependence on regulatory approvals for its Electroceutical devices. Competition from established pharmaceutical companies and medical device manufacturers poses a significant threat. Negative clinical trial results for SofPulse or other devices could severely impact the company's prospects. As an OTC-traded company, ENDV faces risks associated with low liquidity, potential price manipulation, and limited regulatory oversight. Investors should carefully consider these risks before investing in ENDV.
What are the key factors to evaluate for ENDV?
Endonovo Therapeutics, Inc. (ENDV) currently holds an AI score of 43/100, indicating low score. Key strength: Proprietary Electroceutical technology. Primary risk to monitor: Potential: Failure to obtain regulatory approvals for new applications.. This is not financial advice.
How frequently does ENDV data refresh on this page?
ENDV prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ENDV's recent stock price performance?
Recent price movement in Endonovo Therapeutics, Inc. (ENDV) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary Electroceutical technology. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ENDV overvalued or undervalued right now?
Determining whether Endonovo Therapeutics, Inc. (ENDV) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ENDV?
Before investing in Endonovo Therapeutics, Inc. (ENDV), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on OTC-traded companies.
- Financial data may not be current or audited.
- AI analysis pending for ENDV.